# A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects

> **NCT03121716** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 23 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **BIOLOGICAL:** SHR-1210
- **DRUG:** Gemcitabine
- **DRUG:** cis-platinum

## Key facts

- **NCT ID:** NCT03121716
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-26
- **Primary completion:** 2020-07-28
- **Final completion:** 2020-07-31
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2022-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03121716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03121716, "A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03121716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*